
|Articles|October 22, 2012
FDA warns of serious blood disorder resulting from abuse of Opana ER
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablets (Opana ER, Endo).
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Addressing Depression Symptoms Can Significantly Improve Asthma Outcomes
2
President Trump Signs Sweeping, Unprecedented Federal PBM Reform
3
TrumpRx Officially Launches, Introduces Drug Prices
4
What the Newest Landmark PBM Reform Means for the Pharmacy Industry
5























